.Pharmacolibrary.Drugs.ATC.N.N02CC03

Information

Zolmitriptan is a selective serotonin 5-HT1B/1D receptor agonist used for the acute treatment of migraine headaches, with or without aura, in adults. It is approved for use in many countries including the US and Europe.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, following oral administration.

References

1. Yates, RA, et al., & Kemp, J (2002). The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects. European journal of clinical pharmacology 58(4) 247–252. DOI:10.1007/s00228-002-0461-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12136370

2. Eiland, LS, & Hunt, MO (2010). The use of triptans for pediatric migraines. Paediatric drugs 12(6) 379–389. DOI:10.2165/11532860-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21028917

3. Martin, GR (1997). Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia : an international journal of headache 17 Suppl 18 4–14. DOI:10.1177/0333102497017S1802 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9399012

Revisions

• 06/2025 initial generated model